Zelluna Immunotherapy
Blood & Organ Banks · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Ullernchausséen 64, Oslo, Oslo, 0379, No...Phone Number
+46 859478830Website
www.zelluna.comRevenue
$6.3 MillionIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
2
2
2
About Zelluna Immunotherapy
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property position enable it to pursue promising developments in the cell therapy field. Their mission is to transform cancer care by advancing innovative therapies that harness the immune system's capabilities.Explore more
Zelluna Immunotherapy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zelluna Immunotherapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Zelluna Immunotherapy had a recent Job posting/layoffs
Product Launch: Get notified when Zelluna Immunotherapy launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Zelluna Immunotherapy
Check out if Zelluna Immunotherapy is spiking on competitors!
Earning: See what the market has to say on Zelluna Immunotherapy recently announced quarterly report
Funding: Get notified immidiatlly once Zelluna Immunotherapy has new funding data
Zelluna Immunotherapy, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Zelluna Immunotherapy has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Zelluna Immunotherapy is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Zelluna Immunotherapy is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Zelluna Immunotherapy.
Zelluna Immunotherapy financials insights
Gather financial insights about Zelluna Immunotherapy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$8.5M
Other Financing Round
$6M
Zelluna Immunotherapy Tech Stack
A closer look at the technologies used by Zelluna Immunotherapy
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Lateral Move
Executive Move
Executive Moves, Lateral Move
Promotion
Executive Move
Executive Moves, Promotion
Zelluna Immunotherapy News & Media
Zelluna ASA – Disclosure of voting rights of Extraordinary General Meeting
Oslo, September 1, 2026: In connection with the Extraordinary General Meeting of Zelluna ASA to be held on September 9, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement, received proxy-based voting rights without voting instructions (discretionary proxies) for 1,700,157 shares, representing 5.69% of the total voting rights in the Company.Zelluna ASA: Second Quarter 2026 results
Oslo, 20 August 2026 – Zelluna (OSE: ZLNA), a clinical-stage company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the second quarter 2026.Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101
17 August 2026 – Zelluna ASA (OSE: ZLNA) today announced that the Independent Data Monitoring Committee (IDMC) has completed its review of the first patient’s safety data from the first-in-human ZIMA-101 study and has recommended that the study continues as planned.Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down
Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the Company’s Board of Directors (the “Board”).
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zelluna Immunotherapy
Sign Up For FreeTo access detailed company insights
Zelluna is a pioneering company developing novel cell therapies specifically targeting solid cancers to improve treatment outcomes for cancer patients. The company focuses on its proprietary TCR-NK cell therapy platform, which aims to overcome existing challenges in solid cancer treatment. Zelluna's experienced team and strong intellectual property... Read More
